KRAS and familial pancreatic carcinoma: Notably, the PE corrected the KRAS G13D mutation to its wild-type sequence with editing efficiency of 36.1% in HCT116 human colon cancer cells and 18.7% in ASPC-1 pancreatic cancer cells, while minimizing the occurrence of unintended indel formations [33].